



## Cancer Research

Latest Update 02/23/2026

### Cancer

- **LSU LCMC Health Cancer Center**, Innovative and Catalytic Cancer Research ([ICCR](#)) Program. The Pilot Program is designed to support short-term, cancer-relevant projects with strong potential to lead to external funding, high-impact publications, new collaborations, and other outcomes that advance the scientific priorities of the Cancer Center. Projects across the full research spectrum, basic, translational, clinical, and population science, are encouraged.
  - o ~~Letters of Intent submission open: **February 2**~~
  - o ~~Letters of Intent due: **February 20**~~
  - o Application open: **March 9**
  - o Full proposal due: **April 24**
  - o Award notifications: **Early June**
  - o Project start date: **July 1**
  - o The program is open to all Full LSU LCMC Health Cancer Center Members, and it strongly encourages multi-PI and cross-campus collaborations
  - o LOIs must be submitted through [InfoReady](#) ([InfoReady App](#)).
- [Lung Cancer Research Foundation](#) (LCRF) Research Funding Opportunities (Applicants may only apply for one LCRF grant per grant cycle):

- **2026 LCRF Research Grant on Prevention and Early Detection in Lung Cancer.** [Details.](#)
  - LOI submission deadline: **March 10, 2026**
  - Applicants will be notified of their status on April 28, 2026
  - Full proposal submission deadline: **June 2, 2026**
- **2026 LCRF Research Grant on Overcoming Resistance in Lung Cancer.** [Details.](#)
  - LOI submission deadline: **March 10, 2026**
  - Applicants will be notified of their status on April 28, 2026
  - Full proposal submission deadline: **June 2, 2026**
- **2026 LCRF Leading Edge Research Grant Program.** [Details.](#)
  - LOI submission deadline: **March 10, 2026**
  - Applicants will be notified of their status on April 28, 2026
  - Full proposal submission deadline: **June 2, 2026**
- **OUCH-Int'l and LCRF Research Grant Program on the Effects of Air Pollution and Climate Change on Carcinogenesis and Lung Cancer Prevalence.** [Details.](#)
  - Full proposal submission deadline: **June 2, 2026**
- The **Henry & Marilyn Taub Foundation**, [2026 MDS Pilot Research Grants](#) for early-career investigators. To foster innovation and the expansion of MDS research, collaborative efforts with those from non-MDS fields are encouraged.
  - Letter of Intent Deadline: **March 9, 2026**
  - Full Applications are Invited: **April 15, 2026**
  - Full Application Deadline: **July 1, 2026**
  - Award Notification: **September 26, 2026**
  - Funding Start: **December 1, 2026**
- **CDMRP, DOW**, FY 26 Pre-announcements released:
- The [Ovarian Cancer Research Program \(OCRP\)](#) released a pre-announcement for the following funding opportunities:

- o Clinical Trial Award
- o Investigator-Initiated Research Award
- o Ovarian Cancer Academy – Early-Career Investigator Award
- o Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award
- o Pilot Award
- The [Pancreatic Cancer Research Program \(PCARP\)](#) released a pre-announcement for the following funding opportunities:
  - o Focused Pilot Award
  - o Idea Development Award
  - o Translational Research Partnership Award
- The [Melanoma Research Program \(MRP\)](#) released a pre-announcement for the following anticipated funding opportunities:
  - o Idea Award
  - o Melanoma Academy Scholar Award
  - o Team Science Award
  - o Survivorship Research Award
  - o Focused Program Award – Rare Melanomas
- The [Peer Reviewed Cancer Research Program \(PRCRP\)](#) released a pre-announcement for the following anticipated funding opportunities:
  - o Idea Award (New: Established Investigator Option and Early-Career Investigator Option)
  - o Impact Award (with or without Partnering Principal Investigator Option)
  - o Clinical Trial Award
- **NIH**, Dissemination and Implementation Research in Health (**R01** Clinical Trial Optional) ([PAR-25-144](#)), (**R03** Clinical Trial Not Allowed) ([PAR-25-233](#)), (**R21** Clinical Trial Optional) ([PAR-25-143](#)). **Expiration Date: January 08, 2028.**
- **NCI**, National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (**P01** Clinical Trial Optional) ([PAR-23-059](#)). **Expiration Date: May 26, 2026.**
- **NCI, NIMHD, NIAAA**, Interventions to Address Disparities in Liver Diseases and Liver Cancer (**R01** – Clinical Trials Optional) ([PAR-25-299](#)). **Expiration Date: January 8, 2028.**
- **NIH, NCI**, Basic Research in Cancer Health Disparities (**R01** Clinical Trial Not Allowed) ([PAR-25-243](#)). **Expiration Date: January 8, 2028.**

- **NIH, NCI**, Basic Research in Cancer Health Disparities (**R21** Clinical Trial Not Allowed) ([PAR-25-244](#)). Expiration Date: November 17, 2027.
- **NCI**, Toward Translation of Nanotechnology Cancer Interventions (TTNCI; **R01** Clinical Trial Not Allowed) ([PAR-25-336](#)). Expiration Date: November 16, 2027.
- **NCI**, Innovative Research in Cancer Nanotechnology (IRCN; **R01** Clinical Trial Not Allowed) ([PAR-25-106](#)). Expiration Date: May 05, 2026.
- **NCI**, Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (**R01** Clinical Trial Optional) ([PAR-25-175](#)). Expiration Date: January 08, 2028.
- **NCI, NIAAA**, Population Approaches to Reducing Alcohol-related Cancer Risk (**R01** Clinical Trial Optional) ([PAR-25-221](#)). Expiration Date: January 08, 2027.
- **NCI**, Cancer Prevention and Control Clinical Trials Grant Program (**R01** Clinical Trial Required) ([PAR-25-167](#)). Expiration Date: January 08, 2027.
- **NCI**, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (**R01** Clinical Trial Not Allowed) ([PAR-24-304](#)). Expiration Date: October 15, 2026.
- **NCI**, National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (**R01** Clinical Trial Required) ([PAR-25-081](#)). Expiration Date: January 08, 2027.
- **NCI**, Modular R01s in Cancer Control and Population Sciences (**R01** Clinical Trial Optional) ([PA-25-172](#)). Expiration Date: January 08, 2028.
- **NCI**, Molecular Imaging of Inflammation in Cancer (**R01** Clinical Trial Not Allowed) ([PAR-24-311](#)). Expiration Date: January 08, 2028.
- **NCI**, Mechanisms that Impact Cancer Risk after Bariatric Surgery (**R01** Clinical Trial Optional) [PAR-25-043](#), (**R21** Clinical Trial Not Allowed) [PAR-25-044](#). Expiration Date: January 08, 2028.
- **NIH**, Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (**R01** Clinical Trial Not Allowed) ([PAR-25-095](#)); (**R21** Clinical Trials Not Allowed) ([PAR-25-096](#)). Expiration Date: September 08, 2026.

- **NCI**, Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (**R01** Clinical Trial Optional) ([PAR-25-069](#)); (**R21** Clinical Trial Not Allowed) ([PAR-25-070](#)).  
Expiration Date: January 08, 2027.
- **NCI**, Exploratory Grants in Cancer Control (**R21** Clinical Trial Optional) ([PA-25-253](#)).  
Expiration Date: September 08, 2028.
- **NIH** Exploratory/Developmental Research Project Grant (**Parent R21** Clinical Trial Not Allowed) ([PA-25-304](#)). Expiration Date: January 8, 2028.
- **NIH** Exploratory/Developmental Research Project Grant (**Parent R21** Clinical Trial Required) ([PA-25-306](#)). Expiration Date: January 8, 2028.
- **NCI**, Cancer Prevention and Control Clinical Trials Planning Grant Program (**U34** Clinical Trials Optional) ([PAR-25-103](#)); (**R34** Clinical Trials Optional) ([PAR-25-104](#)).  
Expiration Date: October 26, 2027.
- **NCI** Pathway to Independence Award (**K99/R00** Clinical Trial Not Allowed) ([PAR-25-135](#)). Expiration Date: October 15, 2027.
- **NCI**, Assay Validation of High Quality Markers for Clinical Studies in Cancer (**UH2/UH3** Clinical Trial Not Allowed) ([PAR-25-074](#)), (**UH3** Clinical Trials Not Allowed) ([PAR-25-075](#)). Expiration Date: October 15, 2026.
- **AACR, American Association for Cancer Research Funding Opportunities.**  
[Details.](#)
  - [AACR Non-Small Cell Lung Cancer Research Fellowship](#)
    - ~~Letter of Intent Deadline: January 22, 2026~~
    - Application Deadline: **May 7, 2026**
  - [AACR Maximizing Opportunity for New Advancements in Research in Cancer \(MONARCA\) Grant for Latin America](#)
    - ~~Letter of Intent Deadline: January 22, 2026~~
    - Application Deadline: **May 14, 2026**